Completed PHASE3 INTERVENTIONAL NCT00200499

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension

Sponsor: Mylan Bertek Pharmaceuticals

Conditions Hypertension

Interventions Nebivolol

Updated 5 times since 2017 Last updated: Dec 15, 2005 Started: Mar 31, 2002 Completion: Sep 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertension and is currently completed. Mylan Bertek Pharmaceuticals leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mylan Bertek Pharmaceuticals

Data source: Mylan Bertek Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Morgantown, United States